Expedited Access to Biosimilars Act

I

119TH CONGRESS

2D SESSION

H. R. 9661

To amend the Public Health Service Act to codify that the default expectation

for licensure of biological products as biosimilar does not include clinical

studies assessing pharmacodynamics or comparative clinical efficacy, and

for other purposes.